The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C.
Continue reading »Interim data from a Phase 1b trial of Inhibitex's INX-189 demonstrates potent antiviral activity against the Hepatitis C virus.
Continue reading »In the U.S. and Europe, Boceprevir's entrance into the market is being accelerated due to its effectiveness against Hepatitis C.
Continue reading »Pharmasset has released interim study results for several of its Hepatitis C drugs that are in different stages of testing.
Continue reading »Along with Health Canada, the United States Food and Drug Administration has cleared the protocol for Anadys' Phase IIb Hepatitis C study of ANA598 in combination with pegylated interferon and ribavirin.
Continue reading »Designed to stimulate the immune system so the body can produce its own natural interferon, Idera's IMO-2125 posted great results from its Hepatitis C Phase 1 trial.
Continue reading »When added to conventional antiviral therapy, GlobeImmune's investigational, therapeutic Hepatitis C vaccine appears to correct a fundamental deficit in cellular immunity in those with the disadvantaged T/T allele of the IL-28 gene.
Continue reading »Clinical trials in Oxford are gathering evidence that a therapeutic Hepatitis C vaccine can help defeat the virus when combined with antiviral therapy.
Continue reading »Two of Gilead's investigational drugs, GS 9190 and GS 9256, showed high HCV viral suppression rates - especially when combined with ribavirin and pegylated interferon.
Continue reading »In combination with pegylated interferon and ribavirin, Tibotec and Medivir's TMC435 showed high antiviral activity and tolerability in a Phase 2b Hepatitis C study.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
